Skip to content
MARKETS / NASDAQ / SNYR
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Synergy CHC Corp. SNYR

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$30.4M
▼ 12.8% YoY
$-12.3M
▼ 680.8% YoY
In brief

What this company does

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration (“FDA”) -approved investigational new drug (IND) application) that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals. We built our brand portfolio through strategic acquisitions. Our asset-light business model, in which we partner with third-party manufacturers to produce our brand offerings, allows us to scale quickly and profitably while satisfying growing demand. Our second marquee brand, Flat Tummy, consists of a range of lifestyle and wellness products and accessories including tea, shakes, lollipops, supplements, apparel, and exercise accessories.

Written from the business description in Synergy CHC Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 1 April 2026. Every sentence was checked against that document before publication.

Growth
USD 30.4M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 30.4 · Net income -12.3
20M40M-5M-10M201220142016201820232025
Compound annual growth
+8.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−41 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -27.8% · Net -40.6%
-5000%-10000%201220142016201820232025
ROE
FY2018 · ROE -91.9%
-100%-200%201220142016201820232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2018 · FCF 1.2
2.0M4.0M-0.4M-0.8M201220142016201820232025
Net buybacks $M Dividends $M
FY2015 · Dividends 1.2 · Net buybacks —
0.4M0.8M2015

Total assetsUSD 10.2M
EquityUSD -23.1M
CashUSD 2.6M
Gross debtUSD 25.1M
Net debtUSD 22.4M
Current ratio1.22×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320192018201720162015201420132012
Revenue $B0.00.00.00.00.00.00.00.00.0··
Operating income $B−0.00.00.0−0.0−0.00.00.00.0−0.0··
EBITDA $B·0.00.0−0.0−0.00.00.00.0−0.0··
Income tax $B0.00.00.0−0.00.00.00.00.00.00.0·
Net income $B−0.00.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B····0.0−0.00.0−0.0···
EPS, diluted $−1.270.280.86−0.10−0.070.01−0.01−0.11−0.010.000.00
Dividend / sh $···········
Payout %·······−16···
ROE %····−91.96.0−12.7−284.7···
Shares out B0.010.000.010.090.090.090.090.080.060.180.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 52 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 43 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image